These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20472361)

  • 1. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
    Williams S; Buyyounouski M; Kestin L; Duchesne G; Pickles T
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):724-31. PubMed ID: 20472361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Malik R; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
    Krauss D; Kestin L; Ye H; Brabbins D; Ghilezan M; Gustafson G; Vicini F; Martinez A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1064-71. PubMed ID: 20584576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
    Igdem S; Abacioglu U; Cetin I; Alco G; Akgun Z; Sengoz M; Bekiroglu N; Turkan S; Okkan S
    J BUON; 2009; 14(4):629-34. PubMed ID: 20148454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
    Higgins GS; McLaren DB; Kerr GR; Elliott T; Howard GC
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):982-9. PubMed ID: 16750310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer.
    Sharma NK; Li T; Chen DY; Pollack A; Horwitz EM; Buyyounouski MK
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):437-44. PubMed ID: 21050673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Lamb DS; Denham JW; Joseph D; Matthews J; Atkinson C; Spry NA; Duchesne G; Ebert M; Steigler A; Delahunt B; D'Este C
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):385-91. PubMed ID: 20350786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.